The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
A Phase I Pharmacokinetic and Pharmacodynamic Study of OGX-011, a 2′-Methoxyethyl Antisense Oligonucleotide to Clusterin, in Patients With Localized Prostate Cancer
Abstract
BACKGROUND: Clusterin is a cytoprotective chaperone protein that promotes cell survival and confers broad-spectrum treatment resistance. OGX-011 is a 2'-methoxyethyl modified phosphorothioate antisense oligonucleotide that is complementary to clusterin mRNA and has been reported to inhibit clusterin expression and enhance drug efficacy in xenograft models. The primary objective of this clinical study was to determine a biologically effective dose of OGX-011 that would inhibit clusterin expression in human cancer. METHODS: Subjects (n = 25) with localized prostate cancer with high-risk features who were candidates for prostatectomy were treated with OGX-011 by 2-hour intravenous infusion on days 1, 3, and 5 and then weekly from days 8-29 combined with androgen blockade starting on day 1; prostatectomy was performed on days 30-36. Six different doses were tested, from 40 to 640 mg. OGX-011 plasma and prostate tissue concentrations were measured by an enzyme-linked immunosorbent assay method, and the pharmacokinetics of OGX-011 were determined from these data. Prostate cancer tissue, lymph nodes, and serial samples of peripheral blood mononuclear cells were assessed for clusterin expression using quantitative real-time polymerase chain reaction and immunohistochemistry. All statistical tests were two-sided. RESULTS: Only grade 1 and 2 toxicities were observed. The plasma half-life of OGX-011 was approximately 2-3 hours, and the area under the concentration versus time curve and CMAX (peak plasma concentration) increased proportionally with dose (Ptrend < .001). OGX-011 in prostate tissue increased with dose (Ptrend < .001). Dose-dependent decreases in prostate cancer and lymph node clusterin expression were observed by polymerase chain reaction of greater than 90% (Ptrend = .008 and Ptrend < .001, respectively) and by immunohistochemistry (Ptrend < .001 and Ptrend = .01, respectively). CONCLUSIONS: OGX-011 is well tolerated and reduces clusterin expression in primary prostate tumors. The optimal biologic dose for OGX-011 at the schedule used is 640 mg.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hapeman, D. E. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,373
A DISTRIBUTION-FREE k-SAMPLE TEST AGAINST ORDERED ALTERNATIVES
JONCKHEERE, A. R. (1954) · Biometrika · doi:10.1093/biomet/41.1-2.133 · Cited by 1,500
Monia, B. P., Lesnik, E. A., Gonzalez, C., Lima, W. F., McGee, D., Guinosso, C. J., Kawasaki, A. M., Cook, P. D., & Freier, S. M. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85268-7 · Cited by 778
Jones, S. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00155-8 · Cited by 488
Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.
Kyprianou, N., English, H. F., & Isaacs, J. T. (1990) · PubMed · Cited by 478
Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins
Humphreys, D. T., Carver, J. A., Easterbrook-Smith, S. B., & Wilson, M. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.11.6875 · Cited by 455
Waters, J. S., Webb, A., Cunningham, D., Clarke, P. A., Raynaud, F., di Stefano, F., & Cotter, F. E. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1812 · Cited by 454
Bubendorf, L., Kolmer, M., Kononen, J., Koivisto, P., Mousses, S., Chen, Y., Mahlamaki, E., Schraml, P., Moch, H., Willi, N., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.20.1758 · Cited by 350
GLEAVE, M. E., GOLDENBERG, S. L., CHIN, J. L., WARNER, J., SAAD, F., KLOTZ, L. H., JEWETT, M., KASSABIAN, V., CHETNER, M., DUPONT, C., et al. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)65971-x · Cited by 326
Self-citationOverexpression of Clusterin in Human Breast Carcinoma
Redondo, M., Villar, E., Torres-Muñoz, J., Tellez, T., Morell, M., & Petito, C. K. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64552-x · Cited by 243
Miyake, H., Nelson, C. C., Rennie, P. S., & Gleave, M. E. (2000) · PubMed · Cited by 223
Self-citationSensibar, J. A., Sutkowski, D. M., Raffo, A. J., Buttyan, R., Griswold, M. D., Sylvester, S. R., Kozlowski, J. M., & Lee, C. (1995) · PubMed · Cited by 219
July, L. V., Akbari, M., Zellweger, T., Jones, E. C., Goldenberg, S. L., & Gleave, M. E. (2002) · The Prostate · doi:10.1002/pros.10047 · Cited by 213
Self-citationStress-induced transcription of the clusterin/apoJ gene
MICHEL, D., CHATELAIN, G., NORTH, S., & BRUN, G. (1997) · Biochemical Journal · doi:10.1042/bj3280045 · Cited by 194
Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer.
Steinberg, J. J., Oyasu, R., Lang, S., Sintich, S. M., RADEMAKER, A. W., Lee, C., Kozlowski, J. M., & Sensibar, J. A. (1997) · PubMed · Cited by 193
Nemunaitis, J., Holmlund, J. T., Kraynak, M., Richards, D., Bruce, J., Ognoskie, N., Kwoh, T. J., Geary, R., Dorr, A., Von Hoff, D., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3586 · Cited by 173
Chemically Modified Oligonucleotides Exhibit Decreased Immune Stimulation in Mice
Henry, S. P., Stecker, K., Brooks, D., Monteith, D., Conklin, B., & Bennett, C. F. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35315-7 · Cited by 152
Miyake, H., Chi, K. N., & Gleave, M. E. (2000) · PubMed · Cited by 150
Self-citationZellweger, T., Chi, K., Miyake, H., Adomat, H. H., Kiyama, S., Skov, K. A., & Gleave, M. E. (2002) · PubMed · Cited by 147
Self-citationZellweger, T., Miyake, H., Cooper, S. R., Chi, K., Conklin, B., Monia, B. P., & Gleave, M. E. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29459-3 · Cited by 133
Self-citationRudin, C. M., Marshall, J. L., Huang, C. H., Kindler, H. L., Zhang, C., Kumar, D., Gokhale, P. C., Steinberg, J., Wanaski, S., Kasid, U. N., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0642 · Cited by 90
Matsushima, H., Goto, T., Hosaka, Y., Kitamura, T., & Kawabe, K. (1999) · Cancer · Cited by 78
Zellweger, T., Kiyama, S., Chi, K. N., Miyake, H., Adomat, H. H., Skov, K. A., & Gleave, M. E. (2003) · British Journal of Urology · doi:10.1046/j.1464-410x.2003.04349.x · Cited by 77
Self-citationMiyake, H., HARA, S., Arakawa, S., Kamidono, S., & Hara, I. (2002) · The Journal of Urology · doi:10.1016/s0022-5347(01)69130-4 · Cited by 62
Effects of synthetic oligonucleotides on human complement and coagulation∗
Shaw, D. R., Rustagi, P. K., Kandimalla, E. R., Manning, A. N., Jiang, Z., & Agrawal, S. (1997) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00091-9 · Cited by 48
Clusterin and IGFBPs as Antisense Targets in Prostate Cancer
Gleave, M. E., & Jansen, B. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1281.020 · Cited by 39
Self-citationFlutamide-induced liver toxicity including fatal hepatic necrosis
Crownover, R. L., Holland, J., Chen, A., Krieg, R. M., Young, B. K., Roach, M., & Fu, K. K. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(95)02107-8 · Cited by 21
Bubley, G. J. (2000) · The Prostate Journal · doi:10.1046/j.1525-1411.2000.24005.x · Cited by 9
Cited by
Bennett, C. F., & Swayze, E. E. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105654 · Cited by 1,374
Swayze, E. E., Siwkowski, A. M., Wancewicz, E. V., Migawa, M. T., Wyrzykiewicz, T. K., Hung, G., Monia, B. P., & Bennett, A. C. F. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkl1071 · Cited by 469
ANTISENSE OLIGONUCLEOTIDES: FROM DESIGN TO THERAPEUTIC APPLICATION
Chan, J. H., Lim, S., & Wong, W. F. (2006) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2006.04403.x · Cited by 430
Improved targeting of miRNA with antisense oligonucleotides
Davis, S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl183 · Cited by 422
Clusterin in Alzheimer’s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies
Foster, E. M., Dangla-Valls, A., Lovestone, S., Ribe, E. M., & Buckley, N. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00164 · Cited by 381
Metadata
- Authors
- Chi, K. N., Eisenhauer, E., Fazli, L., Jones, E. C., Goldenberg, S. L., Powers, J., Tu, D., & Gleave, M. E.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-09-07
- Volume
- 97
- Issue
- 17
- Pages
- 1287-1296
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2108189527
- Cited by
- 266
- References
- 28
- FWCI
- 10.74
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.